Lineage Cell Therapeutics In (LCTX): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Lineage Cell Therapeutics In (LCTX) following the 2026 Q1 hedge fund 13F filings?

As of today, LCTX has moved +2.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -3.6%. Since the quarter end (March 31, 2026), LCTX gained -19.0% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Lineage Cell Therapeutics In (LCTX)

127 + Investors. Track Smart Money conviction in LCTX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — LCTX

Based on 128 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds added LCTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

128 hedge funds hold LCTX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

〰️

Stable — ownership unchanged year-over-year

fund count last 6Q

The number of hedge funds holding LCTX is almost the same as a year ago (+4 funds, +3% change). No significant rush to buy or sell — institutional backing is holding steady.

🟡

Slight buying edge — 58% buying

60 buying43 selling

Last quarter: 60 funds bought or added vs 43 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~24 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 36 → 17 → 25 → 24. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 23% medium ■ 26% new

66 out of 128 hedge funds have held LCTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

➡️

Steady discovery — ~24 new funds/quarter

19 → 36 → 17 → 25 → 24 new funds/Q

New funds entering each quarter: 36 → 17 → 25 → 24. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 62% veterans vs 29% newcomers

■ 62% veterans ■ 9% 1-2yr ■ 29% new

Entry-cohort mix of 131 holders: 81 (62%) are 2+ year veterans, 12 entered 1–2 years ago, and 38 (29%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

📋

Smaller funds dominant — 16% AUM from top-100

16% from top-100 AUM funds

24 of 128 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

3.7

out of 10

Low Exit Risk

Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	127	119	6.72%
13F Shares	112M	97M	14.94%
Total Value	$176M	$169M	4.5%
New Positions	23	25	-2
Increased Positions	35	30	+5
Closed Positions	15	15	-
Reduced Positions	27	26	+1
Total Calls	2	2	-
Total Puts	1	2	-50.0%
PUT/CALL Ratio	0.5	1.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

127

119

6.72%

13F Shares

112M

97M

14.94%

Total Value

$176M

$169M

4.5%

New Positions

-2

Increased Positions

Closed Positions

Reduced Positions

Total Calls

Total Puts

-50.0%

PUT/CALL Ratio

0.5

1.0

Bullish

Institutional Holders (2026 Q1)

127 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in LCTX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 LCTX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Raffles Associates LP	7.35%	5,362,788	$8.5M
2	Broadwood Capital Inc	5.52%	49,560,992	$78.3M
3	Defender Capital, LLC.	3.77%	6,729,599	$10.6M
4	Red Crane Wealth Management, LLC	0.78%	597,263	$944K
5	Quantessence Capital LLC	0.13%	16,281	$26K
6	Armistice Capital, LLC	0.09%	3,182,799	$5.0M
7	Informed Momentum Co LLC	0.06%	346,615	$548K
8	CTC Alternative Strategies, Ltd.	0.05%	15,307	$24K
9	Catalyst Funds Management Pty Ltd	0.05%	170,300	$269K
10	McMillan Office, Inc.	0.04%	216,000	$341K
11	Diametric Capital, LP	0.02%	59,029	$93K
12	Beirne Wealth Consulting Services, LLC	0.02%	45,000	$71K
13	Define Financial, LLC	0.02%	20,000	$32K
14	ELCO Management Co., LLC	0.02%	20,500	$32K
15	Piscataqua Savings Bank	0.01%	12,499	$20K
16	Fifth Third Bancorp	0.01%	4,600,000	$7.3M
17	Trust Co of Toledo NA /Oh/	0.01%	83,795	$132K
18	Founders Capital Management	0.01%	16,000	$25K
19	Farrow Financial, Inc.	0.01%	11,500	$18K
20	Chapin Davis, INC.	0.01%	20,029	$32K
21	Bridgeway Capital Management, LLC	0.01%	221,000	$349K
22	NINE MASTS CAPITAL Ltd	0.01%	29,194	$46K
23	Lazari Capital Management, INC.	0.01%	10,500	$17K
24	Renaissance Technologies LLC	0.01%	2,125,100	$3.4M
25	Marshall Wace, LLP	0.00%	3,065,033	$4.8M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Lineage Cell Therapeutics In (LCTX)

What does the Smart Money Trend signal show for LCTX?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added LCTX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for LCTX?

Slight buying edge — 58% buying: Last quarter: 60 funds bought or added vs 43 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for LCTX holders?

Smaller funds dominant — 16% AUM from top-100: 24 of 128 holders rank in the top 100 by AUM, but together hold only 16% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held LCTX?

52% of holders stayed for 2+ years: 66 out of 128 hedge funds have held LCTX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Lineage Cell Therapeutics In (LCTX) following the 2026 Q1 hedge fund 13F filings?

As of today, LCTX has moved +2.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -3.6%. Since the quarter end (March 31, 2026), LCTX has gained -19.0% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Lineage Cell Therapeutics In (LCTX)

Smart Money Signals — LCTX

Buying streak — 2 quarters in a row

At the ownership peak (100% of max)

Stable — ownership unchanged year-over-year

Slight buying edge — 58% buying

Steady new buyers — ~24 new funds per quarter

52% of holders stayed for 2+ years

Steady discovery — ~24 new funds/quarter

Veteran-anchored — 62% veterans vs 29% newcomers

Smaller funds dominant — 16% AUM from top-100

Institutional Sentiment Summary — LCTX

Hedge Fund Ownership: LCTX

Market Analysis: LCTX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: LCTX

Is It Too Late to Buy Lineage Cell Therapeutics In (LCTX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: LCTX

Statistics: LCTX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Lineage Cell Therapeutics In (LCTX)

Welcome to 13Foresight!